Diabetic nephropathy (DN) is a major life-threatening complication of diabetes. Renal lesions affect glomeruli and tubules but the pathogenesis is not completely understood. Phospholipids and glycolipids are molecules that carry out multiple cell functions in norm and disease and their role in DN pathogenesis is unknown. We employed high spatial resolution matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) to determine lipid changes in kidneys of eNOS -/-db/db mice, a robust model of DN. Phospholipid and glycolipid structures, localization patterns, and relative tissue levels were determined in individual renal glomeruli and tubules without disturbing tissue morphology. Significant increase in the levels of specific glomerular and tubular lipid species from four different classes, i.e. gangliosides, sulfoglycosphingolipids, lysophospholipids, and phosphatidylethanolamines was detected in diabetic kidneys compared to non-diabetic controls. Inhibition of non-enzymatic oxidative and glycoxidative pathways attenuated the increase in lipid levels and ameliorated renal pathology, even though blood glucose levels remained unchanged. Our data demonstrate that the levels of specific phospho-and glycolipids in glomeruli and/or tubules are associated with diabetic renal pathology. We suggest that hyperglycemia-induced DN pathogenic mechanisms require intermediate oxidative steps that involve specific phospholipid and glycolipid species.
INTRODUCTION
The global epidemic of diabetes is a major health problem. Diabetic nephropathy (DN) can develop in about 1/3 of diabetic individuals and is characterized by specific glomerular and tubular lesions in the kidney. These lesions are associated with progression to end stage renal disease with subsequent requirement for renal dialysis and transplantation (1) . Despite the significance of DN, there is still incomplete understanding of the pathogenic mechanisms, particularly those underlying the differential susceptibility to DN.
Lipids may play a role in DN, but to date, the research focus has been on neutral lipids such as triacylglycerols and cholesterol (2) . Phospho-and glycolipids are two major classes of lipid molecules that carry out many biological functions ranging from regulation of physical properties of cellular membranes to cell signaling (3, 4) . In diabetes, changes in the levels of these lipids in blood and tissues cause dysregulation of different cellular processes associated with pathogenesis (3, (5) (6) (7) (8) (9) . Thus, phospho-and glycolipids may have a role in DN.
Uncovering molecular events that define mechanisms of susceptibility and progression in DN requires knowledge of the identity and spatial localization of biomolecules within glomerular and tubular areas of the kidney. Such knowledge can be obtained using matrix assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS), a rapidly advancing technology that acquires molecular information from thin tissue sections in a spatially-defined manner (10, 11) . The levels and spatial localization of biomolecules can be detected from a single tissue section without the need for specific antibodies or a priori knowledge of what molecules are present. For an imaging experiment, a chemical matrix to aid in the absorption of laser energy and ionization is applied uniformly over the sample. The laser is moved in a raster pattern and a spectrum is collected at every pixel in an ordered array across the tissue. Data can then be displayed as molecular maps of the spatial localization of given m/z 4 values throughout the tissue. Molecular identification can be performed directly on the tissue section by MS/MS analysis.
The present study is the first report of the application of MALDI IMS to investigate molecular changes in renal glomerular and tubular phospho-and glycolipids in DN. We utilized a set of experimental tools: a robust DN mouse model, which develops renal lesions comparable to those found in human disease (12) ; a high spatial resolution MALDI IMS technology; and pyridoxamine (PM), which was employed to elucidate whether hyperglycemia induced oxidative pathways play a role in phospho-and glycolipid changes relevant to DN. PM is an inhibitor of oxidative and glycoxidative reactions and has been shown to act via sequestration of redox active metal ions, scavenging of reactive carbonyl compounds, and scavenging of hydroxyl radical both in vitro and in vivo (13) (14) (15) (16) (17) (18) . We determined molecular changes at the level of a single glomerulus or tubule, which has not been achieved in the previous studies of renal tissues using MALDI IMS (19) (20) (21) . Our data demonstrated that the levels of specific phospho-and glycolipids in glomeruli and/or tubules of the kidney are associated with diabetic renal pathology. Inhibition of glycoxidative pathways, without lowering hyperglycemia, ameliorated lipid levels and renal lesions. We suggest that hyperglycemia-induced DN pathogenic mechanisms require intermediate oxidative steps that involve phospho-and glycolipids.
METHODS

Animal studies
Animal experiments were performed at the AAALAC-accredited animal facilities at Vanderbilt University Medical Center according to institutional guidelines and IACUC-approved experimental protocol. Mice were housed in a pathogen-free barrier facility and given standard by guest, on November 10, 2017 www.jlr.org Downloaded from chow (Lab Diet 5015; PMI Nutrition International, Richmond, IN) and water ad libitum. Upon development of hyperglycemia (about 6 wks of age), eNOS -/-C57BLKS db/db mice were randomized according to body weight and assigned to either diabetic or diabetic/PM treatment groups. Mice in diabetic/PM treatment group received PM in drinking water at a daily dose of 400 mg/kg body weight, based on previously published reports of PM protection from kidney injury in diabetic mice (22) . To minimize possible chemical degradation of PM, a light-sensitive compound, fresh solutions were prepared twice a week and administered in water bottles wrapped in aluminum foil as previously described (23) . PM treatment continued until mice were sacrificed at 22 wks of age. The control group included wild type C57BLKS mice. Kidneys were removed and either fixed for histological analyses by light and electron microscopy or flash frozen in liquid nitrogen and stored at -80°C for IMS analyses.
Determination of blood glucose and urinary albumin excretion
Glucose levels were measured in blood collected from the tail vein using OneTouch glucometer and Ultra test strips (LifeScan, Milpitas, CA) as previously described (12, 24) .
Albumin and creatinine excretion was determined in spot urine collected from individually caged mice using Albuwell-M kits (Exocell Inc, Philadelphia, PA) as previously described (12, 24) .
The assay variability was < 5% in duplicate measurements.
Histological Analyses
Renal histology was assessed in mice at 22 weeks of age. The kidneys were removed and fixed overnight in 10% formalin at 4°C, and 3-μm-thick sections were stained with periodic acidSchiff (PAS) and Jones' silver staining. Histological evaluation by light microscopy was performed without knowledge of the identity of the various groups. A semi-quantitative index was used to evaluate the degree of glomerular mesangial expansion and sclerosis. Each glomerulus on a single section was graded from 0 to 3, where 0 represents no lesion, and 1, 2, and 3 represent mesangial matrix expansion or sclerosis, involving < 25, 25 to 50, and > 50% of the glomerular tuft area, respectively (see Fig. S2 ).
For electron microscopy, kidneys were cut into small tissue blocks (1 mm 3 ) and fixed in 2.5% glutaraldehyde fixative with 0.1 mol/L cacodylate buffer, pH 7.4, overnight at 4°C. After postfixation with 1% osmium tetroxide, tissues were dehydrated in a series of graded ethanol preparations and embedded in epoxy resin (Poly/Bed 812 Embedding Media; Polysciences, Warrington, PA). Ultrathin sections were stained with uranyl acetate and lead citrate. Sections were observed by transmission electron microscopy (H-7000; Hitachi, Tokyo, Japan) at 75 kV to determine TBM and GBM thickness.
Immunohistochemistry
Immunohistochemical detection of fibronectin was performed using an anti-fibronectin antibody (Sigma, St. Louis, MO). The kidney sections then were incubated using the avidinbiotin-horseradish peroxidase technique (Elite Vectastain ABC kit; Vector Laboratories, Burlingame, CA), and staining was visualized using 3,3`-diaminobenzidine.
MALDI mass spectrometry
MALDI TOF Lipid Imaging: Frozen kidneys were sectioned on a cryostat at 8 µm thickness, thaw mounted on conductive indium tin oxide coated glass slides, and dried in a desiccator. The tissue sections were washed by dipping the slide in 50 mM ammonium formate at 4°C three times for five seconds each to remove salts and increase the sensitivity for lipid analysis (25). MALDI matrix was applied using a custom built sublimation apparatus which uses reduced pressure and heat for vapor deposition of the MALDI matrix on to the sample slide Glomerular and tubular signals were evaluated as single ions and the Amadori-PEs were evaluated as the ratio of the Amadori-PE signal to the unmodified PE signal.
Histology Directed IMS:
Frozen kidneys were sectioned as above and processed using a washing procedure described by Yang et al. (27) . Histology-directed IMS was performed as described previously (28), with some modifications. Kidney sections were stained with 0.5% cresyl violet for 30 s followed by an ethanol rinse. Coordinates of the individual glomeruli and tubules within the kidney sections were recorded using a Mirax slide scanner (Zeiss). Trypsin and the MALDI matrix were deposited using an automated acoustic robotic spotter (Portrait 630, database search engine to match tryptic peptide sequences to their respective intact proteins (see Fig. S4 ). The intensity of the fibronectin peptide at m/z 1906 was used to determine the relative deposition of fibronectin in glomeruli from different experimental groups (Fig. 2F ). This increase in fibronectin deposition by IMS was consistent with that determined using classical immunohistochemistry approach (Fig. S5 ).
Statistical analysis
Data were expressed as means  SEM and statistical analysis was performed using At >20 weeks of age, these mice exhibit albuminuria, arteriolar hyalinosis, increased glomerular basement membrane (GBM) thickness, mesangial expansion, mesangiolysis, focal segmental and early nodular glomerulosclerosis, and markedly decreased glomerular filtration rate (12) . In our study, eNOS -/-C57BLKS db/db mice developed significant albuminuria at 6 weeks of age which increased dramatically by 22 weeks of age ( Fig. 1) . Treatment of diabetic mice with PM significantly ameliorated albuminuria at 22 weeks of age ( Fig. 1 ).
Kidneys of three animals from each treatment group were taken for MALDI IMS analyses of lipids. The second set of kidneys from the same three animals in each treatment group was subjected to renal pathology analyses to allow for direct comparison of renal injury and lipid profiles. Diabetic mice exhibited dramatic increase in glomerular and tubular pathologic lesions (Fig. 2B-F) . PM treatment significantly ameliorated these lesions ( Fig. 2B-F) .
Interestingly, PM treatment did not inhibit hyperglycemia itself ( Fig. 2A) . Therefore, use of PM treatment allowed us to compare renal lipid profiles in hyperglycemic animals with significantly different degrees of renal pathology.
Composition of mouse renal glomerular and tubular phospho-and glycolipids. MALDI
IMS was performed on renal sections from three biological replicates in each experimental group (non-diabetic, diabetic, and diabetic + PM). Because DN lesions affect primarily glomeruli and tubules, we focused on the lipid molecular patterns localized specifically within glomerular and tubular areas of the renal cortex. We examined 60-70 glomeruli and/or tubules per mouse in each experimental group. Multiple species that belong to different lipid classes were identified within glomerular and tubular structures (Table S1 ).
We then focused only on those specific phospho-and glycolipid species that exhibited significant changes in glomerular and/or tubular levels in diabetes compared to control. These species belonged to four lipid classes: gangliosides, sulfoglycosphingolipids, lysophospholipids, and phosphatidylethanolamines and are highlighted in Table S1 . (Fig. 3) . Both ganglioside species were localized exclusively to renal glomeruli ( Fig. 3A and B) . However, there was a distinct difference in the response of these species to our experimental treatments. NeuAc-GM3 was detected at relatively high levels that
Glomerular levels of major ganglioside
were not significantly different in all treatment groups (Fig. 3A, top row and 3D ). In contrast, NeuGc-GM3 was present at relatively low levels in the glomeruli of non-diabetic animals but increased ~8-fold in the glomeruli of diabetic mice (Fig. 3A, bottom row and 3D ). Diabetic mice treated with PM had significantly lower levels of NeuGc-GM3 compared to untreated diabetic mice. (Fig. 3A, bottom row and 3D) .
Levels of long-chain series sulfoglycolipids are increased within renal tubules in DN.
Sulfoglycolipids are produced from glycosphingolipids via addition of one or several sulfate They are also enriched in mammalian kidneys where they have been shown to be involved in osmoregulation and acid-base homeostasis (34, 35) . We have identified several species of sulfoglycolipids localized specifically to mouse renal tubules: SM4s (sulfogalactoceramide), SM3 (sulfolactoceramide), SM2a (gangliotriosylceramide sulfate), and SB1a
(gangliotetraosylceramide-bis-sulfate) and their different acyl chain derivatives (Table S1 and Fig. S6 ). There was a significant increase in the levels of sulfoglycolipid species SB1a in diabetic kidneys from 22 wk old eNOS -/-db/db mice compared to controls ( Fig. 4A and B) . This increase was ameliorated in diabetic mice treated with PM ( Fig. 4A and B) . In contrast to SB1a, levels of SM3, a less polar species that possesses a relatively short sugar chain, remained unchanged in the DN model (22 wk old eNOS -/-db/db mice) compared to control ( Fig. 4A and   B ). Tubular localization of both sulfoglycolipids was confirmed by comparing the 10 μm spatial resolution IMS data to a PAS stained image of the same section (Fig. 4C) . Similarly, level of SM4s, another sulfoglycolipid with a short sugar chain, was also unchanged in diabetic tubules compared to controls (data not shown). Interestingly, SM3 and SM4s had very distinct nonoverlapping tubular localization patterns (Fig. S7) .
Major bioactive lysophospholipids are elevated in renal glomeruli in DN.
Bioactive lysophospholipids (LPLs) are important signaling and regulatory molecules involved in multiple pathogenic pathways including inflammation and fibrosis, key features of kidney disease (36, 37) . However, renal LPL levels in DN have not been reported. We have detected LPL species comprising two major classes, lysophosphatidylcholine (LPC) and lysophosphatidic acid (LPA), in the mouse renal glomeruli (Table S1 ). The levels of both LPL classes were significantly increased in glomeruli of diabetic mice (Fig. 5) . Moreover, LPC levels were most prominently increased within those individual glomeruli exhibiting higher levels of fibrosis as determined by PAS staining (Fig. S8 ). Levels were significantly diminished in diabetic mice treated with PM ( Fig. 5B-D) . Other LPL classes such as lysophosphatidylserine, lysophosphatidylglycerol, and lysophosphatidylethanolamine were not detected in our study, possibly due to the sensitivity limits as their reported physiological levels in mouse plasma are 2-to-3 orders of magnitude lower compared to major LPLs (37).
Non-enzymatic modification of phosphatidylethanolamine by glucose is increased in the cortex of the DN kidney. Non-enzymatic adduction of glucose to aminophospholipids has been
shown to increase in diabetic human plasma and animal tissues including kidney (38, 39).
However, with the exception of diabetic atherosclerotic lesions (40), the role of glycated lipids in diabetic complications has not been investigated.
We utilized MALDI IMS to analyze glycation of different phosphatidylethanolamine (PE) species in the kidney of a mouse model of DN. The identities of PE species and their glucose modification (Amadori adduct) were determined in renal tissue sections using characteristic fragmentation patterns generated by tandem MS (Fig. 6 ). Unmodified PE species as well as unmodified plasmalogen PE species, characterized by the presence of a vinyl ether bond at the sn-1 position (41), did not significantly change in diabetes compared to controls (Fig. 6A) .
Several Amadori-PE species, containing glucose adducted to the lipid amino group, were identified in the diabetic kidneys but were not detected in the non-diabetic kidneys (Table   S1 , Table S2 , and Fig. 6A ). MALDI IMS of transverse sections through the kidney showed that these signals were present in the cortex of the kidney. Treatment of diabetic mice with PM, did not significantly affect Amadori-PE levels ( Fig. 6 and Table S2 ), however, a tendency toward lower levels was observed in renal specimens from PM-treated mice (Table S2) .
To determine more precise localization patterns of Amadori-PE species within the renal cortex, a region of the cortex in the diabetic kidney was imaged at high spatial resolution with a 10 µm step size (Fig. 7) . First, we found that PE lipids were not uniformly distributed throughout the cortex but had uniquely localized patterns. Next, we established that the unmodified and the Amadori forms of the same lipid species co-localize to the same areas of the cortex. This can be seen in (Fig. 7B) . The former is localized exclusively to a distinct set of tubules while the latter has a mixed glomerular and tubular localization (Fig. 7C ). Here, we utilized MALDI IMS technology to determine DN-related changes of molecular species from four major lipid classes in renal cortex, including individual glomeruli and tubules, determined directly from thin kidney sections. We employed a mouse model of DN known to exhibit severe renal damage (47) which was also observed in our study ( Fig. 1 and 2 ).
DISCUSSION
Additionally, PM treatment was utilized in one experimental group which showed a reduction in albuminuria (Fig. 1) . This is consistent with the observed protective effects of PM on renal function demonstrated in several diabetic animal models (14, 22, 48, 49) and in clinical trials, particularly at the early stages of the disease (50, 51) .
Previous studies reported changes in ganglioside levels and metabolism in diabetic animal models (52) (53) (54) . However, this is the first report on specific glomerular localization and levels of major gangliosides in DN. Of particular interest is the observed dramatic increase in the levels of NeuGc-GM3 in diabetic glomeruli (Fig. 3) . As sialic acids are synthesized via a branch of the glycolytic pathway, the increased flux through this pathway in diabetes may contribute to such increase. However, since sialic acid NeuAc is a precursor of NeuGc and ganglioside NeuAc-GM3 did not increase in diabetes (Fig. 3A , top row) this mechanism is unlikely. Alternatively, NeuGc-GM3 may derive via non-enzymatic hydroxylation of the acetyl moiety of NeuAc-GM3 by hydroxyl radicals produced in diabetic oxidative stress (55, 56) . This mechanism is consistent with decreased NeuGc-GM3 levels in the glomeruli of diabetic mice treated with PM, which has been shown to scavenge hydroxyl radical under high glucose conditions (16, 57) . Interestingly, unlike in all other mammals, ganglioside NeuGc-GM3 is not metabolically produced in humans and is present only at trace levels in normal human tissues, most likely due to dietary sources (58) . However, NeuGc-GM3 is significantly increased in many human tumors where it may act as xeno-autoantigen causing chronic inflammation (58).
Therefore, it is possible that diabetic oxidative stress facilitates oxidation of NeuAc-GM3 and accumulation of NeuGc-GM3 in glomeruli, thus contributing to chronic inflammation in DN.
Our results suggest that sulfoglycolipids may play a role in DN pathogenesis. The exact mechanism remains to be elucidated. However, it is interesting that isolated rat renal tubules exposed to exogenous glucose in vitro showed increases in the levels of SM2a and SB1a but not SM3 sulfoglycolipids (59) , similar to our results in DN mouse model (Fig. 4) . Experiments using cerebroside sulfotransferase (CST) knock-out mice, which do not synthesize sulfoglycolipids, have demonstrated significant reduction in monocyte infiltration of renal interstitium after ureteral obstruction in the knock-out compared to the wild-type mice. These studies suggested that sulfoglycolipids may promote renal inflammation and tubulointerstitial injury, possibly via ligation of L-selectin (60).
It is well established that lysophospholipids (LPLs) are important signaling and regulatory molecules involved in multiple pathogenic pathways (36, 37) . LPL species may regulate cell signaling through altering the structure and fluidity of a lipid bilayer, particularly above their critical micelle concentration (CMC) (37) . (66, 67) . In the in vitro studies, LPC induced proliferation of cultured mesangial cells via a mechanism involving activation of EGF receptor signaling (68) . LPC is also a ligand for two G-protein coupled receptors G2A and GPR4, which are expressed in many human tissues including kidney (69, 70) . It is yet unknown whether these receptors are involved in pathogenesis of renal disease.
While prior studies have shown the elevated levels of Amadori-PEs in plasma of diabetic patients and in different organs of diabetic animal models (38, 39) , ours is the first report establishing a relationship between glycated PEs and DN. Glycated PEs have been shown to alter the structure and stability of cell membrane proteins and promote lipid peroxidation (40, 71) , thus exhibiting pathogenic potential. Our results suggest that Amadori-PEs play a minor role in DN pathogenesis. The levels of different Amadori-PE species in renal cortex were significantly elevated in diabetes but were not significantly inhibited upon PM treatment, even though a tendency toward lower levels was observed (Table S2 ). The notion that non-oxidative glucose adduction to PE has low pathogenicity is consistent with the previous findings using mice deficient in fructosamine-3-kinase (FN3K), the enzyme that facilitates dissociation of Amadori adducts to amino groups. These mice did not exhibit a pathogenic phenotype in any organs, including kidney, despite having significantly elevated levels of Amadori-modified tissue proteins (72).
In summary, our data demonstrate that the levels of specific phospho-and glycolipids in Figure 1 . Urinary albumin-to-creatinine ratio in diabetic mice and effect of PM treatment. Nondiabetic control C57BLKS and diabetic eNOS -/-C57BLKS db/db mice were housed as described under Methods. PM treatment of diabetic mice (400 mg/kg/day) started at 6 weeks of age and continued until 22 weeks of age. Urinary ACR in diabetic (DB) and diabetic + PM (DB+PM) groups was determined before and at the end of PM treatment; urinary ACR in non-diabetic control group was determined at 22 weeks of age. Each bar graph represents the mean±SEM (n=8). N.S. -not significant. Figure 2 . Renal injury and effect of PM treatment. Pathologic renal lesions were determined only in animals subjected to IMS analysis of renal lipid profiles. Treatments were the same as in Fig.  1. (A) Blood glucose levels. Correlation between tubular basement membrane (TBM) (B) or GBM (C) thickness and albuminuria: non-diabetic control (triangles), diabetic (circles), and diabetic treated with PM (squares). Linear regression lines were calculated using Sigma Plot software. Expansion of renal mesangial matrix (D) and renal sclerosis/fibrosis (E) were scored on a scale of 0 to 3 as described under Methods (see Fig. S1 and S2 for supporting data). Sclerosis/fibrosis score is an average of the scores for global sclerosis, interstitial fibrosis and vascular fibrosis. (F) Glomerular deposition of fibronectin determined by MALDI MS (see Fig.  S4 and S5 for supporting data). Each bar graph represents the mean±SEM. * -p<0.05, diabetic vs. non-diabetic groups; ** -p<0.05, diabetic vs. diabetic + PM groups; n=3. 
FIGURE LEGENDS
